| |
| |
|
| Insider
Information: |
Bolzon Bradley J Phd |
| Relationship: |
Director, 10% Owner |
| City: |
Menlo Park |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
21,851 |
|
|
Indirect Shares
|
13,354,534 |
|
|
| Direct
Value |
$152,083 |
|
|
|
Indirect Value
|
$96,162,164 |
|
|
| Total
Shares |
13,376,385 |
|
|
| Total
Value |
$96,314,247 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
3
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
1
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
-1.0
|
| Percentage
Gain/Loss : |
 -15.0%
|
-33.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Paratek Pharmaceuticals Inc |
PRTK |
10% Owner |
2006-05-15 |
0 |
2006-05-15 |
13,713 |
Premium* |
|
|
Flexion Therapeutics Inc |
FLXN |
Director, 10% Owner |
|
0 |
2014-02-18 |
3,206,807 |
Premium* |
|
|
Phaserx, Inc. |
PZRX |
10% Owner |
|
0 |
2016-05-23 |
1,931,094 |
Premium* |
|
|
Crispr Therapeutics Ag |
CRSP |
Director |
2021-06-29 |
0 |
2021-07-19 |
498,558 |
Premium* |
|
|
Black Diamond Therapeutics, Inc. |
BDTX |
Director, 10% Owner |
2020-12-14 |
21,851 |
2020-12-14 |
5,606,424 |
Premium* |
|
|
Monte Rosa Therapeutics, Inc. |
GLUE |
Director, 10% Owner |
2021-06-28 |
0 |
2021-06-28 |
2,097,938 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-07-19 |
4 |
AS |
$125.67 |
$1,264,348 |
I/I |
(10,000) |
148,831 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-06-29 |
4 |
AS |
$145.92 |
$7,106,341 |
D/D |
(47,536) |
0 |
0 |
% |
|
| GLUE |
Monte Rosa Therapeutics, ... |
Director |
– • • |
2021-06-28 |
4 |
A |
$0.00 |
$0 |
I/I |
8,455,912 |
1,940,043 |
0 |
- |
|
| GLUE |
Monte Rosa Therapeutics, ... |
Director |
– • • |
2021-06-28 |
4 |
B |
$19.00 |
$3,000,005 |
I/I |
157,895 |
2,097,938 |
2.25 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-06-28 |
4 |
AS |
$150.65 |
$3,106,783 |
D/D |
(20,375) |
0 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-06-28 |
4 |
AS |
$150.65 |
$1,524,799 |
I/I |
(10,000) |
158,831 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-06-28 |
4 |
A |
$0.00 |
$0 |
I/I |
248,625 |
6,018 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-06-28 |
4 |
AS |
$0.00 |
$0 |
I/I |
(1,285,027) |
0 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
47,536 |
47,536 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-06-11 |
4 |
AS |
$125.62 |
$1,266,118 |
D/D |
(10,000) |
20,375 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-03-22 |
4 |
AS |
$129.36 |
$4,020,667 |
D/D |
(30,374) |
30,375 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,213 |
60,749 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-03-01 |
4 |
AS |
$0.00 |
$0 |
I/I |
(338,165) |
0 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
I/I |
60,068 |
4,012 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-02-19 |
4 |
S |
$147.79 |
$25,497,840 |
I/I |
(171,003) |
168,831 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-02-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,285,027) |
0 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
47,536 |
47,536 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2021-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
248,625 |
6,018 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2020-12-16 |
4 |
AS |
$147.00 |
$1,095,089 |
I/I |
(7,352) |
339,834 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2020-12-16 |
4 |
AS |
$147.00 |
$1,139,177 |
D/D |
(7,648) |
0 |
0 |
% |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-12-14 |
4 |
A |
$0.00 |
$0 |
I/I |
617 |
307 |
0 |
- |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
11 |
21,851 |
0 |
- |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-12-14 |
4 |
AS |
$0.00 |
$0 |
I/I |
(21,401) |
0 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2020-12-10 |
4/A |
AS |
$140.62 |
$4,730,448 |
D/D |
(33,000) |
7,648 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2020-12-10 |
4 |
AS |
$140.62 |
$4,730,448 |
I/I |
(33,000) |
314,186 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
